Achieve Life Sciences Reports 74-80% Median Reduction In Smoking In Study

Achieve Life Sciences Inc ACHV a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation.

The primary endpoint was the reduction in daily smoking, a self-reported measure.

Across all treatment arms, subjects on cytisinicline experienced a 74-80-percent median reduction in the number of cigarettes smoked over a 25-day treatment period — compared to a 62-percent reduction in the placebo arms. 

Achieve Life Sciences shares were trading down by 5.67 percent to $3.42 after the open Tuesday. 

Related Links:

Slack's IPO: What You Need To Know

7 Stocks To Watch For June 11, 2019

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsGeneralsmokingtobacco
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!